Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Systemic Sclerosis (Scleroderma) - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides an overview of the Systemic Sclerosis (Scleroderma) (Immunology) pipeline landscape.
Scleroderma is a group of rare diseases that involve the hardening and tightening of the skin and connective tissues. Symptoms include muscle pains, joint pain and swelling, ulcers occurring on fingertips, bloating of the tummy and diarrhea or constipation. Treatment includes antibiotic, pain relievers and immunosuppressant.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Systemic Sclerosis (Scleroderma) - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides comprehensive information on the therapeutics under development for Systemic Sclerosis (Scleroderma) (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Systemic Sclerosis (Scleroderma) (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Systemic Sclerosis (Scleroderma) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical and Discovery stages are 1, 6, 23, 15, 1, 2, 42 and 5 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 4 and 1 molecules, respectively.
Systemic Sclerosis (Scleroderma) (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Systemic Sclerosis (Scleroderma) (Immunology).
- The pipeline guide reviews pipeline therapeutics for Systemic Sclerosis (Scleroderma) (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Systemic Sclerosis (Scleroderma) (Immunology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Systemic Sclerosis (Scleroderma) (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Systemic Sclerosis (Scleroderma) (Immunology)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Systemic Sclerosis (Scleroderma) (Immunology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Systemic Sclerosis (Scleroderma) (Immunology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
'
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Systemic Sclerosis (Scleroderma) - Overview
Systemic Sclerosis (Scleroderma) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Systemic Sclerosis (Scleroderma) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Systemic Sclerosis (Scleroderma) - Companies Involved in Therapeutics Development
Systemic Sclerosis (Scleroderma) - Drug Profiles
Mar 14, 2022: Chemomab reports on two scientific presentations that support the potential therapeutic utility of CM-101 in Systemic Sclerosis
Mar 01, 2022: Cantargia reports positive preclinical efficacy data for CAN10 demonstrating anti-fibrotic and anti-inflammatory effects in systemic sclerosis
Dec 15, 2021: Kyowa Kirin announces application for partial change of approved indication of LUMICEF for Systemic Sclerosis in Japan
Dec 13, 2021: Cantargia reports positive results for CAN10 antibody in preclinical systemic sclerosis model
Dec 07, 2021: Prometheus Biosciences reports positive topline phase 1 data on lead therapeutic candidate PRA023; expands indications to include Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD)
Dec 02, 2021: Emerald Health Pharmaceuticals’ novel drug candidate demonstrates significant anti-inflammatory and anti-fibrotic activity in multi-organ fibrosis preclinical model
Nov 08, 2021: Cantargia reports progress in manufacturing process development and provides update on clinical trial preparations for CAN10
Oct 14, 2021: Blade Therapeutics announces FDA orphan drug designation granted to Cudetaxestat for treatment of systemic sclerosis
Jun 14, 2021: Gesynta Pharma announces significant progress across development program for first-in-class drug candidate GS-248
May 24, 2021: Daewoong Pharmaceutical's fibrosis drug 'DWN12088' additionally designated as an orphan drug by the US FDA
Apr 01, 2021: Kadmon doses first patient in open-label phase 2 clinical trial of Belumosudil in systemic sclerosis
Mar 31, 2021: Phase-2 clinical trial of MT-7117 initiated in the U.S., Canada, and Europe for the rare disease, diffuse cutaneous systemic sclerosis (dcSSc)
Mar 19, 2021: Cantargia reports positive preclinical safety and efficacy results in the CAN10 project
Mar 11, 2021: Vicore Pharma’s drug candidate C21 dilates peripheral resistance vessels in fibrotic disease
Mar 04, 2021: Genentech’s Actemra becomes the first biologic therapy approved by the FDA for slowing the rate of decline in pulmonary function in adults With systemic sclerosis-associated interstitial lung disease, a rare, debilitating condition
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Systemic Sclerosis (Scleroderma), 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Companies, 2022 (Contd..1)
Number of Products under Development by Companies, 2022 (Contd..2)
Number of Products under Development by Companies, 2022 (Contd..3)
Number of Products under Development by Companies, 2022 (Contd..4)
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Products under Development by Companies, 2022 (Contd..2)
Products under Development by Companies, 2022 (Contd..3)
Products under Development by Companies, 2022 (Contd..4)
Products under Development by Companies, 2022 (Contd..5)
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Target, 2022 (Contd..1)
Number of Products by Stage and Target, 2022 (Contd..2)
Number of Products by Stage and Target, 2022 (Contd..3)
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Mechanism of Action, 2022 (Contd..1)
Number of Products by Stage and Mechanism of Action, 2022 (Contd..2)
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Systemic Sclerosis (Scleroderma) - Pipeline by A. Menarini Industrie Farmaceutiche Riunite Srl, 2022
Systemic Sclerosis (Scleroderma) - Pipeline by Acceleron Pharma Inc, 2022
Systemic Sclerosis (Scleroderma) - Pipeline by Accuitis Pharmaceuticals Inc, 2022
Systemic Sclerosis (Scleroderma) - Pipeline by AKL Research and Development Ltd, 2022
Systemic Sclerosis (Scleroderma) - Pipeline by Allysta Pharmaceuticals Inc, 2022
Systemic Sclerosis (Scleroderma) - Pipeline by Amgen Inc, 2022
Systemic Sclerosis (Scleroderma) - Pipeline by AnaMar AB, 2022
Systemic Sclerosis (Scleroderma) - Pipeline by Annji Pharmaceutical Co Ltd, 2022
Systemic Sclerosis (Scleroderma) - Pipeline by APIE Therapeutics Inc, 2022
Systemic Sclerosis (Scleroderma) - Pipeline by arGentis Pharmaceuticals LLC, 2022
Systemic Sclerosis (Scleroderma) - Pipeline by Aryogen Pharmed Co, 2022
Systemic Sclerosis (Scleroderma) - Pipeline by AstraZeneca Plc, 2022
Systemic Sclerosis (Scleroderma) - Pipeline by Atlantic Healthcare Plc, 2022
Systemic Sclerosis (Scleroderma) - Pipeline by Aurora Research Institute LLC, 2022
Systemic Sclerosis (Scleroderma) - Pipeline by Avotres Inc, 2022
Systemic Sclerosis (Scleroderma) - Pipeline by Beijing Toll Biotech Co Ltd, 2022
Systemic Sclerosis (Scleroderma) - Pipeline by Biogen Inc, 2022
Systemic Sclerosis (Scleroderma) - Pipeline by Biomendics LLC, 2022
Systemic Sclerosis (Scleroderma) - Pipeline by Blade Therapeutics Inc, 2022
Systemic Sclerosis (Scleroderma) - Pipeline by BriaCell Therapeutics Corp, 2022
Systemic Sclerosis (Scleroderma) - Pipeline by Bristol-Myers Squibb Co, 2022
Systemic Sclerosis (Scleroderma) - Pipeline by Cantargia AB, 2022
Systemic Sclerosis (Scleroderma) - Pipeline by Castle Creek Biosciences Inc, 2022
Systemic Sclerosis (Scleroderma) - Pipeline by Celdara Medical LLC, 2022
Systemic Sclerosis (Scleroderma) - Pipeline by Centessa Pharmaceuticals Plc, 2022
Systemic Sclerosis (Scleroderma) - Pipeline by Certa Therapeutics Pty Ltd, 2022
Systemic Sclerosis (Scleroderma) - Pipeline by Chemomab Therapeutics Ltd, 2022
Systemic Sclerosis (Scleroderma) - Pipeline by Chugai Pharmaceutical Co Ltd, 2022
Systemic Sclerosis (Scleroderma) - Pipeline by Civi Biopharma Inc, 2022
Systemic Sclerosis (Scleroderma) - Pipeline by CohBar Inc, 2022
Systemic Sclerosis (Scleroderma) - Pipeline by Corbus Pharmaceuticals Inc, 2022
Systemic Sclerosis (Scleroderma) - Pipeline by Coya Therapeutics Inc, 2022
Systemic Sclerosis (Scleroderma) - Pipeline by CSL Ltd, 2022
Systemic Sclerosis (Scleroderma) - Pipeline by Cumberland Pharmaceuticals Inc, 2022
Systemic Sclerosis (Scleroderma) - Pipeline by Cureveda LLC, 2022
Systemic Sclerosis (Scleroderma) - Pipeline by D&D Pharmatech Co Ltd, 2022
Systemic Sclerosis (Scleroderma) - Pipeline by Daewoong Pharmaceutical Co Ltd, 2022
Systemic Sclerosis (Scleroderma) - Pipeline by Emerald Health Sciences Inc, 2022
Systemic Sclerosis (Scleroderma) - Pipeline by FibroBiologics LLC, 2022
Systemic Sclerosis (Scleroderma) - Pipeline by Foresee Pharmaceuticals Co Ltd, 2022
Systemic Sclerosis (Scleroderma) - Pipeline by Fresenius Kabi SwissBioSim GmbH, 2022
Systemic Sclerosis (Scleroderma) - Pipeline by Galapagos NV, 2022
Systemic Sclerosis (Scleroderma) - Pipeline by Galecto Inc, 2022
Systemic Sclerosis (Scleroderma) - Pipeline by Genentech USA Inc, 2022
Systemic Sclerosis (Scleroderma) - Pipeline by GenKyoTex SA, 2022
Systemic Sclerosis (Scleroderma) - Pipeline by Genmab AS, 2022
Systemic Sclerosis (Scleroderma) - Pipeline by Genrix (Shanghai) Biopharmaceutical Co Ltd, 2022
Systemic Sclerosis (Scleroderma) - Pipeline by Gesynta Pharma AB, 2022
Systemic Sclerosis (Scleroderma) - Pipeline by Gilead Sciences Inc, 2022
Systemic Sclerosis (Scleroderma) - Pipeline by GlaxoSmithKline Plc, 2022
Systemic Sclerosis (Scleroderma) - Pipeline by GNI Group Ltd, 2022
Systemic Sclerosis (Scleroderma) - Pipeline by Horizon Therapeutics Plc, 2022
Systemic Sclerosis (Scleroderma) - Pipeline by iBio Inc, 2022
Systemic Sclerosis (Scleroderma) - Pipeline by Ichnos Sciences Inc, 2022
Systemic Sclerosis (Scleroderma) - Pipeline by Iltoo Pharma, 2022
Systemic Sclerosis (Scleroderma) - Pipeline by ImmuneMed Inc, 2022
Systemic Sclerosis (Scleroderma) - Pipeline by Johnson & Johnson, 2022
Systemic Sclerosis (Scleroderma) - Pipeline by Kadmon Holdings Inc, 2022
Systemic Sclerosis (Scleroderma) - Pipeline by Leadiant Biosciences Inc, 2022
Systemic Sclerosis (Scleroderma) - Pipeline by LightOx Ltd, 2022
Systemic Sclerosis (Scleroderma) - Pipeline by Link Genomics Inc, 2022
Systemic Sclerosis (Scleroderma) - Pipeline by Luminary Therapeutics Inc, 2022
Systemic Sclerosis (Scleroderma) - Pipeline by Mallinckrodt Plc, 2022
Systemic Sclerosis (Scleroderma) - Pipeline by MDI Therapeutics Inc, 2022
Systemic Sclerosis (Scleroderma) - Pipeline by Mitsubishi Tanabe Pharma Corp, 2022
Systemic Sclerosis (Scleroderma) - Pipeline by Ono Pharmaceutical Co Ltd, 2022
Systemic Sclerosis (Scleroderma) - Pipeline by Opsidio LLC, 2022
Systemic Sclerosis (Scleroderma) - Pipeline by Panorama Researchama Research, 2022
Systemic Sclerosis (Scleroderma) - Pipeline by Patagonia Pharmaceuticals LLC, 2022
Systemic Sclerosis (Scleroderma) - Pipeline by PDX Pharmaceuticals LLC, 2022
Systemic Sclerosis (Scleroderma) - Pipeline by Peptinov SAS, 2022
Systemic Sclerosis (Scleroderma) - Pipeline by Pfizer Inc, 2022
Systemic Sclerosis (Scleroderma) - Pipeline by Prometheus Biosciences Inc, 2022
Systemic Sclerosis (Scleroderma) - Pipeline by RadBio, 2022
Systemic Sclerosis (Scleroderma) - Pipeline by Recursion Pharmaceuticals Inc, 2022
Systemic Sclerosis (Scleroderma) - Pipeline by Regeneron Pharmaceuticals Inc, 2022
Systemic Sclerosis (Scleroderma) - Pipeline by Resolys Bio Inc, 2022
Systemic Sclerosis (Scleroderma) - Pipeline by Ribomic Inc, 2022
Systemic Sclerosis (Scleroderma) - Pipeline by Riptide Bioscience Inc, 2022
Systemic Sclerosis (Scleroderma) - Pipeline by Seagen Inc, 2022
Systemic Sclerosis (Scleroderma) - Pipeline by Shanghai YaKe Biotechnology Co Ltd, 2022
Systemic Sclerosis (Scleroderma) - Pipeline by Signablok Inc, 2022
Systemic Sclerosis (Scleroderma) - Pipeline by Takeda Pharmaceutical Co Ltd, 2022
Systemic Sclerosis (Scleroderma) - Pipeline by Talaris Therapeutics Inc, 2022
Systemic Sclerosis (Scleroderma) - Pipeline by Thirona Bio Inc, 2022
Systemic Sclerosis (Scleroderma) - Pipeline by Timber Pharmaceuticals Inc, 2022
Systemic Sclerosis (Scleroderma) - Pipeline by TRACON Pharmaceuticals Inc, 2022
Systemic Sclerosis (Scleroderma) - Pipeline by Tvardi Therapeutics Inc, 2022
Systemic Sclerosis (Scleroderma) - Pipeline by Unity Biotechnology Inc, 2022
Systemic Sclerosis (Scleroderma) - Pipeline by Vicore Pharma AB, 2022
Systemic Sclerosis (Scleroderma) - Pipeline by Welichem Biotech Inc, 2022
Systemic Sclerosis (Scleroderma) - Dormant Projects, 2022
Systemic Sclerosis (Scleroderma) - Dormant Projects, 2022 (Contd..1)
Systemic Sclerosis (Scleroderma) - Dormant Projects, 2022 (Contd..2)
Systemic Sclerosis (Scleroderma) - Dormant Projects, 2022 (Contd..3)
Systemic Sclerosis (Scleroderma) - Discontinued Products, 2022
List of Figures
Number of Products under Development for Systemic Sclerosis (Scleroderma), 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Number of Products by Top 10 Targets, 2022
Number of Products by Stage and Top 10 Targets, 2022
Number of Products by Top 10 Mechanism of Actions, 2022
Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Number of Products by Top 10 Routes of Administration, 2022
Number of Products by Stage and Top 10 Routes of Administration, 2022
Number of Products by Top 10 Molecule Types, 2022
Number of Products by Stage and Top 10 Molecule Types, 2022
